Treatment of Atopic Dermatitis With Dupilumab in a Renal Transplant Patient

Kha, Connie; Raji, Kehinde; Chisolm, Sarah

doi:10.1097/der.0000000000000560

Cited by 12 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). Full texts of 571 records were assessed, of which 25 met our eligibility criteria 10–34 . Eleven studies were conducted in Europe, 10 in the United States, 2 studies in Asia, 1 in Australia, and 1 study in Mexico.…”

Section: Resultsmentioning

confidence: 99%

“…In addition to the study by Bosma et al, 25 5 additional studies (2 case reports, 3 cohorts) reported a total of 13 participants with renal disease, including hydronephrosis, renal insufficiency, and end-stage renal disease. 19 , 20 , 25 , 26 , 28 , 31 Three studies examined dupilumab treatment, 20 , 25 , 31 1 study used cyclosporine treatment, 26 1 study examined systemic corticosteroid treatment, 19 and 1 study did not specify the systemic treatment used. 28 Choi et al 26 examined treatment with ciclosporin and reported that 1 patient with chronic kidney disease and 1 patient with end-stage renal failure on dialysis at the start of study, out of 92 patients in total.…”

Section: Resultsmentioning

confidence: 99%

“…Varma et al 31 presented a case report of a 22-month-old patient with a history of hydronephrosis who received 4 weeks of dupilumab. Kha et al 20 presented a case report of a man with end-stage renal disease after kidney transplantation treated with 8 months of dupilumab. Halabi-Tawil et al 19 reported 1 participant with membranous glomerulonephritis treated with systemic corticosteroids.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey

Drucker¹,

Lam²,

Flohr³

et al. 2022

Dermatitis

View full text Add to dashboard Cite

Background: Clinical trials of systemic therapies for atopic dermatitis (AD) often exclude patients based on age and comorbidities.Objectives: We conducted a scoping review of observational studies and survey of International Eczema Council (IEC) members on the treatment of AD in patients with liver disease, renal disease, viral hepatitis, HIV, or history of malignancy.Methods: We searched MEDLINE via Ovid, Embase via Ovid, and Web of Science from inception to September 14, 2020. We mapped the available evidence on the use of cyclosporine, methotrexate, azathioprine, mycophenolate, systemic corticosteroids, and dupilumab for AD in older adults (≥65 years) and adults with the previously mentioned comorbidities. We surveyed IEC members on their preferred systemic medications for each patient population.Results: We identified 25 studies on the use of systemic medications in special populations of adults with AD. Although IEC members preferred dupilumab as the first-line systemic agent across all special populations, many could not identify viable third-line systemic therapy options for some populations.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey

Drucker¹,

Lam²,

Flohr³

et al. 2022

Dermatitis

View full text Add to dashboard Cite

show abstract

“…Although renal transplant participants are less likely to develop PTAA compared to other transplants, they may suffer from pruritus related to compromised renal function [ 66 ]. Dupilumab has also been shown in two case reports to successfully treat uremic pruritus in renal transplant patients without safety concern [ 66 , 67 ].…”

Section: Methodsmentioning

confidence: 99%

Practical Management of Patients with Atopic Dermatitis on Dupilumab

Papp

Hong

Lansang

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Dupilumab is approved to treat moderate-to-severe atopic dermatitis (AD) in several countries in patients as young as 6 years of age. Since its approval, practical issues related to the use of dupilumab for AD have arisen, with particular interest in transitioning from current therapies and managing medication overlap, considerations for special populations of patients with AD, and management of potential adverse events. Methods This article aims to review the literature addressing several practical management issues related to dupilumab use for AD and to provide a framework for clinical decision-making in these circumstances and sub-populations. Each statement was reviewed, revised and voted on by authors to provide their level of agreement and degree of uncertainty for each statement. Results An agreement level > 80% was achieved for all of the statements. Conclusion The expert panel provides statements considering the practical management of patients with AD taking dupilumab to inform clinical decision-making in specific but frequently encountered clinical situations. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-021-00586-w.

show abstract

“…[32][33][34] Several case reports have reported the safety and efficacy of utilizing the IL-4 inhibitor, dupilumab, to treat atopic dermatitis in patients post-transplant. [35][36][37] The case reports include renal, heart, and liver recipients who received dupilumab within the first year post-transplant for atopic dermatitis. All patients received tacrolimus, mycophenolate, and corticosteroids and they all experienced symptomatic improvement without any adverse effects.…”

Section: Changes To Induction and Maintenance Immunosuppressionmentioning

confidence: 99%

The use of non‐transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician

Szczepanik

Choi

Brady

et al. 2022

Clinical Transplantation

View full text Add to dashboard Cite

Biologics have become the forefront of medicine for management of autoimmune conditions, leading to improved quality of life. Many autoimmune conditions occur in solid organ transplant (SOT) recipients and persist following transplant. However, the use of biologics in this patient population is not well studied, and questions arise related to risk of infection and adjustments to induction and maintenance immunosuppression. Guidelines have been published highlighting management strategies of biologics around the time of elective surgical procedures, but this is not always feasible in urgent situations, especially with deceased donor transplantation. The aim of this review is to summarize the current literature regarding the use of these agents in solid organ transplant recipients, and specifically address induction and maintenance immunosuppression, as well as the need for alternative infective prevention strategies to create This paper represents the opinion of the Immunology/Transplantation Practice and Research Network of the American College of Clinical Pharmacy. It does not necessarily represent an official ACCP commentary, guideline, or statement of policy or position.

show abstract

Treatment of Atopic Dermatitis With Dupilumab in a Renal Transplant Patient

Cited by 12 publications

References 3 publications

Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey

Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey

Practical Management of Patients with Atopic Dermatitis on Dupilumab

The use of non‐transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician

Contact Info

Product

Resources

About